Drug Profile
Research programme: antiarrhythmic agents - sanofi-aventis
Alternative Names: SAR114646; SAR114646ALatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class Antiarrhythmics
- Mechanism of Action L-type calcium channel antagonists; Potassium channel antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Arrhythmias
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Arrhythmias in France (IV)
- 03 Sep 2008 Pharmacodynamics data from preclinical trials in Arrhythmias presented at the ESC Congress 2008: Annual Congress of the European Society of Cardiology (ESC-2008) ,
- 01 Jun 2006 Preclinical trials in Arrhythmias in France (IV)